Management of del(5q) MDS

被引：1
|
作者：
Giagounidis, A. [1 ]
机构：
[1] St Johannes Hosp, Duisburg, Germany
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70035-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).
    Zemanova, Zuzana
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Izakova, Silvia
    Sarova, Iveta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [33] Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
    Jan Krönke
    Emma C. Fink
    Paul W. Hollenbach
    Kyle J. MacBeth
    Slater N. Hurst
    Namrata D. Udeshi
    Philip P. Chamberlain
    D. R. Mani
    Hon Wah Man
    Anita K. Gandhi
    Tanya Svinkina
    Rebekka K. Schneider
    Marie McConkey
    Marcus Järås
    Elizabeth Griffiths
    Meir Wetzler
    Lars Bullinger
    Brian E. Cathers
    Steven A. Carr
    Rajesh Chopra
    Benjamin L. Ebert
    Nature, 2015, 523 : 183 - 188
  • [34] Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
    Kroenke, Jan
    Fink, Emma C.
    Hollenbach, Paul W.
    MacBeth, Kyle J.
    Hurst, Slater N.
    Udeshi, Namrata D.
    Chamberlain, Philip P.
    Mani, D. R.
    Man, Hon Wah
    Gandhi, Anita K.
    Svinkina, Tanya
    Schneider, Rebekka K.
    McConkey, Marie
    Jaeras, Marcus
    Griffiths, Elizabeth
    Wetzler, Meir
    Bullinger, Lars
    Cathers, Brian E.
    Carr, Steven A.
    Chopra, Rajesh
    Ebert, Benjamin L.
    NATURE, 2015, 523 (7559) : 183 - U102
  • [35] ROLE OF LENALIDOMIDE IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (MDS) WITH DEL(5Q) ASSOCIATED WITH PURE RED CELL APLASIA (PRCA)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A.
    HAEMATOLOGICA, 2013, 98 : 691 - 692
  • [36] Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications
    Adema, Vera
    Palomo, Laura
    Kerr, Cassandra M.
    Walter, Wencke
    Przychodzen, Bartlomiej
    Hutter, Stephan
    Laframboise, Thomas
    Diez-Campelo, Maria
    Mallo, Mar
    Nazha, Aziz
    Xicoy, Blanca
    Meggendorfer, Manja
    Carraway, Hetty E.
    Haferlach, Claudia
    Sekeres, Mikkael A.
    Visconte, Valeria
    Haferlach, Torsten
    Sole, Francesc
    Maciejewski, Jaroslaw P.
    BLOOD, 2019, 134
  • [37] Correlation between occurrence of cytopeniasand response to lenalidomide therapy in del 5q MDS patients
    Sekeres, A.
    Maciejewski, J. P.
    Giagounidis, A.
    Wride, K.
    Knight, R.
    List, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 83 - 84
  • [38] THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)
    Schemenau, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Kuendgen, A.
    Bug, G.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S157 - S157
  • [39] CURRENT TREATMENT OF MDS WITH DELETION 5Q
    Sekeres, M.
    LEUKEMIA RESEARCH, 2023, 128
  • [40] Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q)
    Fink, Emma C.
    Kroenke, Jan
    Hurst, Slater N.
    Udeshi, Namrata D.
    Svinkina, Tanya
    Schneider, Rebekka K.
    McConkey, Marie E.
    Jaeras, Marcus
    Bullinger, Lars
    Carr, Steven A.
    Ebert, Benjamin L.
    BLOOD, 2014, 124 (21)
12345